Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease

• Status: Completed
• Trial end date: 2016-05-23
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether pramipexole and bromocriptine are effective in the treatment of non-motor symptoms in Parkinson's Disease.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sandoz
• Treatments: Bromocriptine; Pramipexole

Criteria

Inclusion Criteria:

• Parkinson's disease patients in accordance with UK Queensquare Brain Bank

• modified Hoehn & Yahr stage <3

• Dopamine agents(Levodopa, dopamine agonists) naive patients, or the patients who have discontinued the agents at least four weeks before the screening in case of using the dopamine agents are administered before.

Exclusion Criteria:

• K-MMSE<24

• History of drug-induced Parkinsonism

• secondary parkinsonism

• History of schizophrenia or hallucination

• Requirement of treatment with anti-depressants due to depressive disorder

• Pregnant and/or breeding women

• Renal inadequacy